The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1572
ISSUE1572
May 20, 2019
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
May 20, 2019 (Issue: 1572)
The FDA has approved omadacycline (Nuzyra – Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs)...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.